New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTDRNA, ZIOP, EBIO, RGDO, ESPR, KBIO, OMER, ATNM, TGTX, HZNP, FPRXBioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
News For ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 17, 2014
16:54 EDTFPRXFive Prime initiates dosing of RA patients in FPA008 Phase 1 clinical trial
Five Prime Therapeutics discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis, or RA, patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor, or CSF1R. FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.
08:19 EDTDRNADicerna expects to release initial Phase 1 data from DCR-PH1 trial by 2015-end
Dicerna expects to release initial data from a phase 1 clinical trial of DCR-PH1 in patients with PH1 by the end of 2015. In preclinical studies, DCR-PH1 induces potent and long-term inhibition of HAO1 and significantly reduces urinary oxalate levels, while demonstrating long-term tolerability in animal models of PH1. Following an extensive review of rare diseases with gene targets expressed in the liver, Dicerna has prioritized a broad portfolio of research and development opportunities. The company is currently pursuing discovery research on several rare diseases involving the liver and intends to add additional programs over time. Dicerna expects to declare its first DsiRNA-EX conjugate clinical candidate in 2015 for an undisclosed rare disease involving the liver. For competitive reasons, the company does not plan to specify disease areas or therapeutic targets until a program has reached a late preclinical stage.
08:12 EDTDRNADicerna announces license agreement with Tekmira for PH1 program
Dicerna Pharmaceuticals (DRNA) announced a licensing agreement for Dicerna to use Tekmira’s (TKMR) proprietary lipid nanoparticle technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1, a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. This announcement follows the successful testing of DCR-PH1 in combination with Tekmira's LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront, as well as $22 million in potential development milestones, and a mid-single-digit royalty on future PH1 sales. Tekmira’s LNP system has shown in other human clinical studies to provide potent, safe and effective RNA delivery to hepatocytes. Licensing Tekmira’s LNP will streamline the development path for DCR-PH1 and allows Dicerna to focus its LNP efforts on its oncology pipeline.
07:09 EDTESPRAmerican Heart Association to hold a conference
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information
November 13, 2014
14:56 EDTHZNPHorizon Pharma says Watson Labs filed ANDA for generic PENNSAID
Subscribe for More Information
08:16 EDTOMEROmeros price target raised to $28 from $20 at Maxim
Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.
07:32 EDTEBIOEleven Biotherapeutics reports Q3 EPS (66c), two estimates (44c)
Subscribe for More Information
07:06 EDTHZNPHorizon Pharma files to sell 11.66M shares for existing holders
Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.
November 12, 2014
11:34 EDTESPREsperion management holds an investor presentation with a conference call hookup
Subscribe for More Information
08:13 EDTZIOPBoston Biotech to hold a conference
Subscribe for More Information
08:09 EDTHZNPHorizon Pharma announces favorable Markman ruling in RAYOS patent trial
Subscribe for More Information
November 11, 2014
13:14 EDTTGTXTG Therapeutics Phase 3 trial highly likely to succed, says Brean Capital
Subscribe for More Information
November 10, 2014
16:29 EDTFPRXFive Prime reports Q3 EPS (33c), consensus (40c)
Subscribe for More Information
16:26 EDTTGTXTG Therapeutics reports Q3 EPS with items (51c), consensus (32c)
Subscribe for More Information
16:24 EDTESPREsperion completes enrollment for ETC-1002-009
Subscribe for More Information
16:21 EDTESPREsperion reports Q3 EPS (64c), consensus (68c)
As of September 30, cash, cash equivalents and investment securities totaled $58.0M compared with $77.6M at December 31, 2013.
16:17 EDTFPRXFive Prime files to sell $100M in common stock
16:12 EDTOMEROmeros reports Q3 EPS (54c), consensus (59c)
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use